Navigation Links
Scripps Research announces research & license agreement with Janssen Pharmaceuticals
Date:5/7/2013

LA JOLLA, CA May 7, 2013 The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus. Under the agreement Janssen will receive certain license rights to the results of the research. Janssen Pharmaceuticals will collaborate in the research on influenza through its Crucell Vaccine Institute.

"We're delighted to partner with Janssen in this work that could have a significant impact on human health," said Michael A. Marletta, president and CEO of TSRI. "The new agreement leverages the institute's significant strengths in structural biology to move forward new therapies and vaccines."

Scott Forrest, TSRI's vice president for business development, added, "This deal is the latest example of our corporate partnership strategy, in which we seek focused collaborations to match companies' specific areas of interest with areas of expertise among multiple TSRI labs."

The new agreement builds on research on the influenza virus conducted jointly by TSRI and Janssen's Crucell Vaccine Institute. Previous collaborations have resulted in several high-impact publications, most recently in August 2012 in the journal Science.

Seasonal flu typically causes more than 200,000 hospitalizations and 36,000 deaths every year in the United States, according to estimates by the U.S. Centers for Disease Control. Pandemics pose a greater dangerthe Spanish Flu of 1918-1919 may have killed 50 million people worldwide.

The new strategic collaboration with Janssen follows TSRI's announcement of a five-year agreement with Bristol-Myers Squibb last June; that agreement covered the development of chemistry methodologies and related work.

Forrest notes that promising future areas for corporate partnerships at TSRI include Oncology, Neurodegeneration and Immunology.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
2. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
3. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
4. Scripps Research Institute scientists develop antidote for cocaine overdose
5. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
6. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
7. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
8. Scripps Florida scientists identify neurotranmitters that lead to forgetting
9. Plastic trash altering ocean habitats, Scripps study shows
10. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
11. Esther B. OKeeffe Foundation gives $2 million to the Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... , March 2, 2017 Who risk to ... Download the full report: https://www.reportbuyer.com/product/4313699/ ... FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology: